CTDH News and Press, Ctd Holdings Inc

Conference Brings Together Medical Researchers and Health Professionals to Exchange Information on Lysosomal Diseases Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases...

The FDA has signed-off Phase 3 trial evaluating Cyclo Therapeutics's ([[CTDH]] +8.0%) lead candidate Trappsol Cyclo (Hydroxypropyl-β-cyclodextrin), for the treatment of Niemann-Pick Disease Type C, a rare inherited disorder in which the body is unable to transport choles...

Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol ® Cyclo™ for treatment of Niemann-Pick Disease Type C Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for t...

Cyclo Therapeutics is proud to sponsor the conference for the 5 th consecutive year Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer&#...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that 3 additional patients have completed the 48-week Phase I/II stud...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group...

The Company is also a proud supporter of the NNPDF Conference for the 5 th year Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C1 (NPC1) and Alzheimer’s Diseas...

Favorable risk/benefit analysis outlined in report to FDA Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced tha...

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, Issued a press release titled “Cyclo Therapeutics Inc. Announces Positive Top ...

Thinly traded nano cap Cyclo Therapeutics ( OTCQB:CTDH -6.6% ) announces topline results from 25 participants in two clinical trials, a Phase 1 and a Phase 1/2 , assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of two and three dose regimen...